Journal Mobile Options
Table of Contents
Vol. 104, No. 4, 2000
Issue release date: March 2001

Brain Natriuretic Peptide Is a Predictor of Anthracycline-Induced Cardiotoxicity

Okumura H. · Iuchi K. · Yoshida T. · Nakamura S. · Takeshima M. · Takamatsu H. · Ikeno A. · Usuda K. · Ishikawa T. · Ohtake S. · Matsuda T.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Anthracyclines are effective antineoplastic drugs, but they frequently cause dose-related cardiotoxicity. The cardiotoxicity of conventional anthracycline therapy highlights a need to search for methods that are highly sensitive and capable of predicting cardiac dysfunction. We measured the plasma level of brain natriuretic peptide (BNP) to determine whether BNP might serve as a simple diagnostic indicator of anthracycline-induced cardiotoxicity in patients with acute leukemia treated with a daunorubicin (DNR)-containing regimen. Thirteen patients with acute leukemia were treated with a DNR-containing regimen. Cardiac functions were evaluated with radionuclide angiography before chemotherapies. The plasma levels of atrial natriuretic peptide (ANP) and BNP were measured at the time of radionuclide angiography. Three patients developed congestive heart failure after the completion of chemotherapy. Five patients were diagnosed as having subclinical heart failure after the completion of chemotherapy. The plasma levels of BNP in all the patients with clinical and subclinical heart failure increased above the normal limit (40 pg/ml) before the detection of clinical or subclinical heart failure by radionuclide angiography. On the other hand, BNP did not increase in the patients without heart failure given DNR, even at more than 700 mg/m2. The plasma level of ANP did not always increase in all the patients with clinical and subclinical heart failure. These preliminary results suggest that BNP may be useful as an early and sensitive indicator of anthracycline-induced cardiotoxicity.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Lenaz L, Page JA: Cardiotoxicity of adriamycin and related anthracyclines. Cancer Treat Rev 1976;3:111–120.

    External Resources

  2. Buzdar AU, Marcus C, Smith TL, Blumenschein GR: Early and delayed clinical cardiotoxicity of doxorubicin. Cancer 1985;55:2761–2765.
  3. Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, Muggia FM: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91:710–717.

    External Resources

  4. Ewer MS, Ali MK, Mackay B, Wallace S, Valdivieso M, Legha SS, Benjamin RS, Haynie TP: A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving adriamycin. J Clin Oncol 1984;2:112–117.

    External Resources

  5. Hausdorf G, Morf G, Beron G, Erttmann R, Winkler K, Landbeck G, Keck EW: Long term doxorubicin cardiotoxicity in childhood: Non-invasive evaluation of the contractile state and diastolic filling. Br Heart J 1988;60:309–315.
  6. Sudoh T, Kangawa K, Minamino N, Matsuo H: A new natriuretic peptide in porcine brain. Nature 1988;332:78–81.
  7. Mukoyama M, Nakao K, Hosoda K, Suga S, Saito Y, Ogawa Y, Shirakami G, Jougasaki M, Obata K, Yasue H, Kambayashi Y, Inouye K, Imura H: Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991;87:1402–1412.
  8. Yoshimura M, Yasue H, Okumura K, Ogawa H, Jougasaki M, Mukoyama M, Nakao K, Imura H: Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 1993;87:464–469.
  9. Omland T, Aakvaag A, Bonarjee VVS, Caidahl K, Lie RT, Nilsen DWT, Sundsfjord JA, Dickstein K: Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Circulation 1996;93:1963–1969.
  10. Omland T, Barvik S, Aakvaag A, Aarsland T, Dickstein K: Plasma atrial natriuretic factor concentration during maximal cardiopulmonary exercise in men with mild heart failure. Int J Cardiol 1990;29:179–184.
  11. Kono M, Yamaguchi A, Tsuji T, Misaka A, Igano K, Ueki K, Fujishima M, Ueda A, Inouye K, Nakao K, Imura H: An immunoradiometric assay for brain natriuretic peptide in human plasma. Kaku Igaku Gijutsu 1993;13:2–7.
  12. Myers CE, McGuire WP, Liss RH, Ifrim I, Grotzinger K, Young RC: Adriamycin: The role of lipid peroxidation in cardiac toxicity and tumor response. Science 1977;197:165–167.
  13. Doroshow JH: Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res 1983;43:460–472.
  14. Kusuoka H, Futaki S, Koretsune Y, Kitabatake A, Suga H, Kamada T, Inoue M: Alterations of intracellular calcium homeostasis and myocardial energetics in acute adriamycin-induced heart failure. J Cardiovasc Pharmacol 1991;18:437–444.
  15. Holmberg SR, Williams AJ: Patterns of interaction between anthraquinone drugs and the calcium-release channel from cardiac sarcoplasmic reticulum. Circ Res 1990;67:272–283.
  16. Wakasugi S, Wada A, Hasegawa Y, Nakano S, Shibata N: Detection of abnormal cardiac adrenergic neuron activity in adriamycin-induced cardiomyopathy with iodine-125-metaiodobenzylguanidine. J Nucl Med 1992;33:208–214.
  17. Ito H, Miller SC, Billingham ME, Akimoto H, Torti SV, Wade R, Gahlmann R, Lyons G, Kedes L, Torti FM: Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro. Proc Natl Acad Sci USA 1990;87:4275–4279.

    External Resources

  18. Rajagopalan S, Politi PM, Sinha BK, Myers CE: Adriamycin-induced free radical formation in the perfused rat heart: Implications for cardiotoxicity. Cancer Res 1988;48:4766–4769.
  19. Speyer JL, Green MD, Zeleniuch-Jacquotte A, Wernz JC, Rey M, Sanger J, et al: ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 1992;10:117–127.
  20. Speyer JL, Green MD, Kramer E, Rey M, Sanger J, Ward C, et al: Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med 1988;319:745–752.

    External Resources

  21. Steinberg JS, Cohen AJ, Wasserman AG, Cohen P, Ross AM: Acute arrhythmogenicity of doxorubicin administration. Cancer 1987;60:1213–1218.

    External Resources

  22. Steinherz LI, Steinherz PG, Tan CT, Heller G, Murphy ML: Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991;266:1672–1677.
  23. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP: Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991;324:808–815.
  24. Billingham Me, Bristow MR: Evaluation of anthracyclin cardiotoxicity: Predictive ability and functional correlation of endomyocardial biopsy. Cancer Treat Symp 1984;3:71–76.
  25. Mason JW, Bristow MR, Billingham ME, Daniels JR: Invasive and noninvasive methods of assessing adriamycin cardiotoxic effects in man: Superiority of histopathologic assessment using endomyocardial biopsy. Cancer Treat Rep 1978;62:857–864.

    External Resources

  26. Alexander J, Dainiak N, Berger HJ, Goldman L, Johnstone D, Reduto L, Duffy T, Schwartz P, Gottschalk A, Zaret BL: Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med 1979;300:278–283.
  27. Piver MS, Marchetti DL, Parthasarathy KL, Bakshi S, Reese P: Doxorubicin hydrochloride (Adriamycin) cardiotoxicity evaluated by sequential radionuclide angiocardiography. Cancer 1985;56:76–80.

    External Resources

  28. Lipshultz SE, Sanders SP, Goorin AM, Krischer JP, Sallan SE, Colan SD: Monitoring for anthracycline cardiotoxicity. Pediatrics 1994;93:433–437.
  29. Borow KM, Henderson IC, Neuman A, Colan S, Grady S, Papish S, Goorin A: Assessment of left ventricular contractility in patients receiving doxorubicin. Ann Intern Med 1983;99:750–756.

    External Resources

  30. Bauch M, Ester A, Kimura B, Victoria BE, Kedar A, Phillips MI: Atrial natriuretic peptide as a marker for doxorubicin-induced cardiotoxic effects. Cancer 1992;69:1492–1497.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50